| pubmed-article:15827342 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15827342 | lifeskim:mentions | umls-concept:C0039796 | lld:lifeskim |
| pubmed-article:15827342 | lifeskim:mentions | umls-concept:C1449849 | lld:lifeskim |
| pubmed-article:15827342 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:15827342 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:15827342 | pubmed:dateCreated | 2005-4-13 | lld:pubmed |
| pubmed-article:15827342 | pubmed:abstractText | The Ras-Raf-MEK-ERK (ERK) pathway is a logical therapeutic target because it represents a common downstream pathway for several key growth factor tyrosine kinase receptors which are often mutated or overexpressed in human cancers. Although considered mainly growth-promoting, in certain contexts, this pathway also seems to be apoptosis-suppressing. Several novel agents targeting this pathway have now been developed and are in clinical trials. One of the most interesting new agents is BAY 43-9006. Although initially developed as a Raf kinase inhibitor, it can also target several other important tyrosine kinases including VEGFR-2, Flt-3, and c-Kit, which contributes to its antiproliferative and antiangiogenic properties. To date, encouraging results have been seen with BAY 43-9006, particularly in renal cell cancers which are highly vascular tumors. This review will provide an overview of the ERK signaling pathway in normal and neoplastic tissue, with a specific focus on novel therapies targeting the ERK pathway at the level of Raf kinase. | lld:pubmed |
| pubmed-article:15827342 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15827342 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15827342 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15827342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15827342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15827342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15827342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15827342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15827342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15827342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15827342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15827342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15827342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15827342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15827342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15827342 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15827342 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:15827342 | pubmed:issn | 1535-7163 | lld:pubmed |
| pubmed-article:15827342 | pubmed:author | pubmed-author:SiuLillian... | lld:pubmed |
| pubmed-article:15827342 | pubmed:author | pubmed-author:HedleyDavidD | lld:pubmed |
| pubmed-article:15827342 | pubmed:author | pubmed-author:SridharSrikal... | lld:pubmed |
| pubmed-article:15827342 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15827342 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:15827342 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15827342 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15827342 | pubmed:pagination | 677-85 | lld:pubmed |
| pubmed-article:15827342 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:meshHeading | pubmed-meshheading:15827342... | lld:pubmed |
| pubmed-article:15827342 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15827342 | pubmed:articleTitle | Raf kinase as a target for anticancer therapeutics. | lld:pubmed |
| pubmed-article:15827342 | pubmed:affiliation | Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Suite 5-210, Toronto, Ontario, Canada M5G 2M9. | lld:pubmed |
| pubmed-article:15827342 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15827342 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15827342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15827342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15827342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15827342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15827342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15827342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15827342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15827342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15827342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15827342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15827342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15827342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15827342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15827342 | lld:pubmed |
